Abstract: A method of producing a polyether polyol includes reacting a low molecular weight initiator with one or more monomers in the presence of a polymerization catalyst, and the low molecular weight initiator has a nominal hydroxyl functionality of at least 2. The one or more monomers includes at least one selected from propylene oxide and butylene oxide. The polymerization catalyst is a Lewis acid catalyst having the general formula M(R1)1(R2)1(R3)1(R4)0 or 1, whereas M is boron, aluminum, indium, bismuth or erbium, R1, R2, R3, and R4 are each independent, R1 includes a fluoroalkyl-substituted phenyl group, R2 incudes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, R3 includes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, and optional R4 includes a functional group or functional polymer group, R1 being different from at least one of R2 and R3.

Abstract: A method of producing a polyether polyol includes reacting a low molecular weight initiator with ethylene oxide in the presence of a polymerization catalyst, and the low molecular weight initiator has a nominal hydroxyl functionality at least 2. The polymerization catalyst is a Lewis acid catalyst having the general formula M(R1)1(R2)1(R3)1(R4)0 or 1, whereas M is boron, aluminum, indium, bismuth or erbium, R1, R2, R3, and R4 are each independent, R1 includes a fluoroalkyl-substituted phenyl group, R2 incudes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, R3 includes a fluoroalkyl-substituted phenyl group or a fluoro/chloro-substituted phenyl group, and optional R4 includes a functional group or functional polymer group, R1 being different from at least one of R2 and R3.

Abstract: A method and apparatus for producing product packages comprises operating first and second feedback control loops where product package weight is averaged and used to determine one of two possible adjustments to change the product fill rate and the volume of the product. The feedback loops operate in one of a plurality of index levels. The first feedback loop seeks to improve performance by making adjustments to the fill rate and volume of the product, while incrementally moving to more stable index levels requiring tighter tolerances and package weight averages based on more product packages. The second feedback loop seeks to preserve stability by making its own adjustments to the fill rate and volume of the product if large product package weight fluctuations are sensed. The second feedback loop can move operation to less stable index levels having wider tolerances and package weight averages based on fewer product packages.

Abstract: A method and apparatus for producing product packages comprises operating first and second feedback control loops where product package weight is averaged and used to determine one of two possible adjustments to change the product fill rate and the volume of the product. The feedback loops operate in one of a plurality of index levels. The first feedback loop seeks to improve performance by making adjustments to the fill rate and volume of the product, while incrementally moving to more stable index levels requiring tighter tolerances and package weight averages based on more product packages. The second feedback loop seeks to preserve stability by making its own adjustments to the fill rate and volume of the product if large product package weight fluctuations are sensed. The second feedback loop can move operation to less stable index levels having wider tolerances and package weight averages based on fewer product packages.

Abstract: Systems and methods are described herein that provide user(s) with a customized landing page that is based on a location (e.g., a business or organization) at which the user is located. The customized landing page may be configured to enable a consumer to access the Internet via an Internet hotspot provided by the business or organization. The customized landing page may require the consumer(s) to perform certain actions before enabling a consumer to access the Internet. Such actions include, but are not limited to, viewing advertisements, providing demographic information and/or contact information, and/or interacting with one or more services. Upon connecting to the Internet, various performance indicators associated with the consumer(s) may be determined. An administrator of a hotspot provider may be enabled to view the performance indicator(s) and market themselves accordingly.

Abstract: Systems and methods are described herein that provide user(s) with a customized landing page that is based on a location (e.g., a business or organization) at which the user is located. The customized landing page may be configured to enable a consumer to access the Internet via an Internet hotspot provided by the business or organization. The customized landing page may require the consumer(s) to perform certain actions before enabling a consumer to access the Internet. Such actions include, but are not limited to, viewing advertisements, providing demographic information and/or contact information, and/or interacting with one or more services. Upon connecting to the Internet, various performance indicators associated with the consumer(s) may be determined An administrator of a hotspot provider may be enabled to view the performance indicator(s) and market themselves accordingly.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and an alkylating agent, which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and cyclophosphamide. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vinca alkaloids, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vincristine. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a platinum compound which has anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and carboplatin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from anthracyclines and topisomerase II inhibitors, which have anti-tumor activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from etoposide, and doxorubicin. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

Abstract: This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula or a pharmaceutically acceptable salt or ester thereof; wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy, and wherein each of R1, R2 and R3 may be present at any of the available positions 1 to 8; and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (—CH═) groups may be replaced by an aza (—N═) group; and wherein any two of R1, R2 and R3 may additionally together represent the group —CH

Abstract: This invention relates to a method of treating cancer, and particularly a method including the steps of administering to a mammal in need of such treatment, either simultaneously or sequentially, (i) a compound selected from a paclitaxel and docetaxel, and (ii) a compound of the formula 1

Abstract: A method of treating neoplastic disease wherein a patient in need of such treatment is administered an effective amount of a radiation-activated cytotoxin prodrug (RACP) which has low toxicity, which is reducible by reducing agents generated by the radiolysis of water and which, upon reduction, releases a sufficient amount of a cytotoxic effector of sufficient cytotoxic potency to kill tumor cells. The tumor cells are irradiated with ionizing radiation to reduce the prodrug which is present at the locus of the tumor cells to release the cytotoxic effector.

Abstract: The invention provides nitroaniline derivatives represented by general formula (I) where the nitro group is substituted at any one of the available benzene positions 2-6; where R and A separately represent the groups NO.sub.2, CN, COOR.sup.1, CONR.sup.1 R.sup.2, CSNR.sup.1 R.sup.2 or SO.sub.2 NR.sup.1 R.sup.2 and A is substituted at any one of the available benzene positions 2-6; where B represents N(CH.sub.2 CH.sub.2 halogen).sub.2 or N(CH.sub.2 CH.sub.2 OSO.sub.2 R.sup.3).sub.2 substituted at any one of the available benzene positions; and where R.sup.1, R.sup.2 and R.sup.3 separately represent H, or lower alkyl optionally substituted with hydroxyl, ether, carboxy or amino functions, including cyclic structures, or R.sup.1 and R.sup.2 together with the nitrogen form a heterocyclic structure, and pharmaceutical preparations containing them. These compounds have activity as hypoxia-selective cytotoxins, reductively-activated prodrugs for cytotoxins, hypoxic cell radiosensitisers, and anticancer agents.

Abstract: New cobalt complexes of nitrogen mustard alkylating agents which have been found to have hypoxia-selective antitumor properties and are thereby useful antitumor agents are described.

Abstract: An electro-mechanical lock which includes a housing having right and left side cavities in which a latch block may be selectively mounted to cooperatively retain a tongue extending from a door or gate which slides or swings from either the left or right side. The latch block includes a pivotable "J" latch which is engageable within a slot in the tongue extending from a gate or door to be locked as the tongue engages the "J" latch as the gate or door is closed. A latch retainer is operable to secure the latch in an engaged position with the tongue and is retractable by a solenoid or mechanical element controlled by a key operated cylinder to release the "J" latch and allow opening of the gate or door.

Abstract: A digital control system for controlling the flow of traffic in selected directions in response to digital signals transmitted from a common transmitting control unit to multiple separate receiving traffic control units respectively associated with each controlled direction. The transmitting unit includes a transmitter and digital command code generator operative when actuated to transmit a character in the form of a digital signal specific for one of the receiving units. Each receiving unit includes traffic control indicators operative in different modes of display indications visible to traffic flowing in the direction to be controlled by that unit.